Raf 1 Antibody

A-Raf, B-Raf and c-Raf (Raf-1) are the main effectors recruited by GTP-bound Ras to activate the MEK-MAP kinase pathway (1) . Activation of c-Raf is the best understood and involves phosphorylation at multiple activating sites including Ser338, Tyr341, Thr491, Ser494, Ser497 and Ser499 (2) . p21-activated protein kinase (PAK) has been shown to phosphorylate c-Raf at Ser338 and the Src family phosphorylates Tyr341 to induce c-Raf activity (3, 4) . Ser338 of c-Raf corresponds to similar sites in A-Raf (Ser299) and B-Raf (Ser445), although this site is constitutively phosphorylated in B-Raf (5) . Inhibitory 14-3-3 binding sites on c-Raf (Ser259 and Ser621) can be phosphorylated by Akt and AMPK, respectively (6, 7) . While A-Raf, B-Raf and c-Raf are similar in sequence and function, differential regulation has been observed (8) . Of particular interest, B-Raf contains three consensus Akt phosphorylation sites (Ser364, Ser428 and Thr439) and lacks a site equivalent to Tyr341 of c-Raf (8, 9) . The B-Raf mutation V600E results in elevated kinase activity and is commonly found in malignant melanoma (10) . Six residues of c-Raf (Ser29, Ser43, Ser289, Ser296, Ser301 and Ser642) become hyperphosphorylated in a manner consistent with c-Raf inactivation. The hyperphosphorylation of these six sites is dependent on downstream MEK signaling and renders c-Raf unresponsive to

Avruch, J. et al. (1994) Trends Biochem. Sci. 19, 279-283. Chong, H. et al. (2001) EMBO J. 20, 3716-3727. King, A. J. et al. (1998) Nature 396, 180-183. Fabian, J. R. et al. (1993) Mol. Cell Biol. 13, 7170-7179. Mason, C. S. et al. (1999) EMBO J. 18, 2137-2148. Zimmermann, S. and Moelling, K. (1999) Science 286, 1741-1744. Sprenkle, A. B. et al. (1997) FEBS Lett. 403, 254-258. Marais, R. et al. (1997) J. Biol. Chem. 272, 4378-4383. Guan, K. L. et al. (2000) J. Biol. Chem. 275, 27354-27359. Davies, H. et al. (2002) Nature 417, 949-954. Dougherty, M. K. et al. (2005) Mol. Cell 17, 215-224.